Change over period: —
NSE · EMCURE
EMCURE
-1.1% from the 52-week high · +74.6% above the low
Emcure Pharmaceuticals Ltd develops, manufactures, and markets pharmaceutical products across multiple therapeutic segments. The company emphasizes quality, regulatory compliance, and global market outreach in both branded and generic medicines.
The short version. EMCURE reported revenue of ₹2,820 crore for Sep 2026, up 24.2% from a year earlier. Net profit was ₹326 crore (up 34.2% year on year). Return on equity was 18.7% in Mar 2026. Promoter holding was 77.82% in Sep 2026, down 0.12 points over 8 quarters.
1 · The price
How has the stock traded?
EMCURE trades 1.1% below its 52-week high and 74.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹2,820 cr.
Sep 2026 net profit of ₹326 cr.
0.8 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2820 | 2580 | 2470 | 2363 | 2270 | 2101 | 2116 | 1963 |
| Net profit | 326 | 294 | 243 | 231 | 243 | 207 | 189 | 154 |
| Net margin % | 11.5 | 11.4 | 9.9 | 9.8 | 10.7 | 9.9 | 8.9 | 7.8 |
| EPS (₹) | 17.16 | 15.5 | 12.84 | 12.16 | 12.84 | 10.92 | 9.97 | 8.11 |
Annual
| FY2026 | FY2025 | |
|---|---|---|
| Revenue | 9204 | 7896 |
| Net profit | 924 | 681 |
| Net margin % | 10.0 | 8.6 |
| EPS (₹) | 48.76 | 35.96 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 18.7% in Mar 2026; debt to equity is 0.24.
Profitability · 2 years
Returns and margins
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Return on equity % | 18.7 | 15.3 |
| Return on capital % | 25.1 | 20.6 |
| EBITDA margin % | 20.0 | 19.2 |
| Net margin % | 10.0 | 8.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 0.12 pts over 8 quarters.
Up 1.89 pts over 8 quarters.
Up 4.62 pts over 8 quarters.
+14 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 77.94 | 77.92 | 77.91 | 77.89 | 77.88 | 77.87 | 77.83 | 77.82 | -0.12 |
| FII | 3.05 | 3.07 | 2.86 | 3.29 | 3.59 | 3.35 | 4.88 | 4.94 | +1.89 |
| DII | 3.87 | 3.44 | 2.84 | 4.37 | 6.1 | 6.1 | 8.46 | 8.49 | +4.62 |
| Public | 15.14 | 15.57 | 16.39 | 14.46 | 12.44 | 12.68 | 8.83 | 8.75 | -6.39 |
Mutual fund holdings · Oct 2026
76 schemes hold this stock
62 the month before.
- Bajaj Finserv Healthcare Fund3.76% of NAV
- ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND3.06% of NAV
- Baroda BNP Paribas Small Cap Fund2.63% of NAV
- ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND1.89% of NAV
- the Quantum Flexi Cap Fund1.78% of NAV
- Kotak Healthcare Fund1.63% of NAV
- Baroda BNP Paribas Health and Wellness Fund1.57% of NAV
- The Wealth Company Large & Mid Cap Fund1.4% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for EMCURE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about EMCURE
What is the EMCURE share price?
EMCURE (EMCURE) last closed at ₹2,344.70, up 0.42% on the day. Its 52-week range is ₹1,337.40 to ₹2,361.70.
What is the market cap of EMCURE?
EMCURE has a market capitalisation of about ₹44,310 crore. Its price-to-earnings ratio is 49.0.
How are EMCURE's latest results?
EMCURE reported revenue of ₹2,820 crore for Sep 2026, up 24.2% from a year earlier. Net profit was ₹326 crore (up 34.2% year on year). Return on equity was 18.7% in Mar 2026. Promoter holding was 77.82% in Sep 2026, down 0.12 points over 8 quarters.
Who owns EMCURE?
As of Sep 2026, shareholding was: Promoter 77.82%, FII 4.94%, DII 8.49%, Public 8.75%.
How many mutual funds hold EMCURE?
76 mutual fund schemes held EMCURE in October 2026. That compares with 62 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 14 Aug 2025 · Final Dividend - Rs. 3
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.